Escient is a clinical-stage pharmaceutical company focused on discovering and developing first-in-class therapies to address serious, unserved medical needs. The company is led by an experienced team with specific expertise in GPCR drug discovery and development. Escient's pipeline consists of two novel antagonists targeting MRGPRX4 for the treatment of cholestatic pruritis and MRGPRX2 for mast cell mediated disorders.

Sectors
Healthcare
Life Sciences
First Invested
2022
Early
Company Status
Acquired
Acquired by Incyte
Board Members
Matt McAviney, MD